Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study

Ann Palliat Med. 2021 Aug;10(8):8557-8570. doi: 10.21037/apm-21-833. Epub 2021 Aug 3.

Abstract

Background: Since 2020 COVID-19 pandemic became an emergent public sanitary incident. The epidemiology data and the impact on prognosis of secondary infection in severe and critical COVID-19 patients in China remained largely unclear.

Methods: We retrospectively reviewed medical records of all adult patients with laboratory-confirmed COVID-19 who were admitted to ICUs from January 18th 2020 to April 26th 2020 at two hospitals in Wuhan, China and one hospital in Guangzhou, China. We measured the frequency of bacteria and fungi cultured from respiratory tract, blood and other body fluid specimens. The risk factors for and impact of secondary infection on clinical outcomes were also assessed.

Results: Secondary infections were very common (86.6%) when patients were admitted to ICU for >72 hours. The majority of infections were respiratory, with the most common organisms being Klebsiella pneumoniae (24.5%), Acinetobacter baumannii (21.8%), Stenotrophomonas maltophilia (9.9%), Candida albicans (6.8%), and Pseudomonas spp. (4.8%). Furthermore, the proportions of multidrug resistant (MDR) bacteria and carbapenem resistant Enterobacteriaceae (CRE) were high. We also found that age ≥60 years and mechanical ventilation ≥13 days independently increased the likelihood of secondary infection. Finally, patients with positive cultures had reduced ventilator free days in 28 days and patients with CRE and/or MDR bacteria positivity showed lower 28-day survival rate.

Conclusions: In a retrospective cohort of severe and critical COVID-19 patients admitted to ICUs in China, the prevalence of secondary infection was high, especially with CRE and MDR bacteria, resulting in poor clinical outcomes.

Keywords: COVID-19; carbapenem resistant Enterobacteriaceae (CRE); intensive care unit (ICU); multidrug resistant Acinetobacter baumannii; secondary infection.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • COVID-19*
  • Coinfection* / drug therapy
  • Cross Infection* / drug therapy
  • Cross Infection* / epidemiology
  • Humans
  • Middle Aged
  • Pandemics
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Anti-Bacterial Agents